Officials from the Dean McGee Eye Institute today announced the dedication of the Institute’s new $46 million, five-story, 78,000-square-foot, world-class research and clinical facility.
Author: The Medical News
MDC Partners acquires majority stake in Concentric Pharma
Concentric Pharma Advertising, one of the largest and fastest-growing healthcare advertising agencies in the country, announced today that MDC Partners, Inc., has acquired a majority stake in the company.
Loma Linda University’s Vision Intervention Program receives Spot screener from PediaVision
PediaVision today announced that Loma Linda University’s Vision Intervention Program is the first in the State of California to receive the revolutionary new vision screener from PediaVision called “Spot.”
Many Canadians are not screening for glaucoma earlier, finds study
Glaucoma is the second leading cause of blindness worldwide. Although it can be treated, new research shows Canadians may not be doing enough to protect themselves. According to a new study by Lawson Health Research Institute’s Dr. Cindy Hutnik, many C…
DSMB authorizes ACT to proceed with next set of patients in stem cell clinical trials
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the independent Data and Safety Monitoring Board (DSMB) overseeing the Company’s two ongoing stem cell clinical trials in the United States authorized …
Embryonic stem cell therapy for incurable Stargardt eye disease
Full Story →
STAAR’s new Visian ICL with CentraFLOW technology showcased at ESCRS congress
STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced the Visian Implantable Collamer Lens (ICL), and new Visian ICL with CentraFLOW technology utilizing the KS-AquaPORT, were …
AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis
Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1.5 million from the Foundation Fighting Blindness to fu…
IRIDEX licenses rights to Ocunetics’ intellectual property
IRIDEX Corporation today announced that it has exclusively licensed the rights to all of the intellectual property of Ocunetics, Inc., a privately held company based in Alamo, California. Ocunetics develops procedure-enabling medical devices that are …
ERWW PR forms Health Buzz Group
Euro RSCG Worldwide PR (ERWW PR) announces the formation of its Health Buzz Group, a global division created in response to growing client interest in big, splashy “wows” from small budgets in quick time frames using traditional and social media to…
Venus Williams withdraws from US Open due to Sjogren syndrome
Sjogren syndrome was in the news recently when tennis player, Venus Williams, was forced to withdraw form the US Open tennis tournament due to symptoms from the disease.
New collaboration reinforces Sanofi’s translational discovery platform for retinal diseases
The Max Planck Society (Max-Planck-Gesellschaft), Germany’s leading basic research organization, announced today that it has signed with Fovea Pharmaceuticals, the Ophthalmology Division of Sanofi, a research collaboration and license agreement to iden…
CHAM experts available to discuss variety of back-to-school issues
Experts from The Children’s Hospital at Montefiore (CHAM) are available for interviews on a variety of back-to-school issues.
Lucentis receives Health Canada approval to treat vision loss from DME
Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from diabetic macular edema, one of the major causes of adult vision loss and an important complication of the growing epidemic of diabetes.
BVES protein may play a role in colon cancer progression
A protein critical in heart development may also play a part in colon cancer progression. Research led by investigators from Vanderbilt-Ingram Cancer Center and the Vanderbilt Eye Institute suggests that the protein BVES (blood vessel endocardial subst…
Bausch + Lomb to launch VICTUS Femtosecond Laser Platform for cataract surgery
Bausch + Lomb, the global leader in eye health, and Technolas Perfect Vision GmbH (TPV), a leading ophthalmology laser company, plan to introduce the VICTUS Femtosecond Laser Platform at the upcoming XXIX Congress of the European Society of Cataract an…
Exonhit consolidated revenues decrease 56% to € 2.4 million for first half of 2011
The Exonhit Supervisory Board met on September 12 to close the consolidated half-year accounts for the six-month period ended June 30, 2011.
Mass. Eye and Ear receives NIAID grant to coordinate Harvard-wide Project on Antibiotic Resistance
The Massachusetts Eye and Ear Infirmary has received an $11 million grant from the National Institute of Allergy and Infectious Disease, the largest National Institutes of Health grant in this hospital’s187-year history, to coordinate the Harvard-wide …
OptiMedica’s Catalys Precision Laser System for cataract receives European CE mark
Global ophthalmic company OptiMedica Corp. has announced that it has received CE mark approval to market its Catalys Precision Laser System for cataract surgery in Europe.
Amakem receives €18m in Series A round of funding
Amakem NV today announced it has raised €18m with a syndicate of leading life sciences investors to advance its ophthalmology drug development portfolio and progress its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.